Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05441761 | Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL | unknown | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05426811 | Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients | unknown | Phase 1 / Phase 2 | 50 | China Medical University, ChinaOTHER | 0 | Jun 29, 2022 | clinicaltrials |
| NCT05122221 | CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers | unknown | Phase 1 | 12 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | Jun 28, 2022 | clinicaltrials |
| NCT05435274 | Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 380 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 28, 2022 | clinicaltrials |
| NCT04632316 | A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 33 | Glycostem Therapeutics BVINDUSTRY | 5 | Jun 21, 2022 | clinicaltrials |
| NCT05369312 | Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients | unknown | Phase 1 | 230 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04258072 | Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma. | unknown | Phase 1 | 24 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04631835 | Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer | unknown | Phase 1 | 54 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 15, 2022 | clinicaltrials |
| NCT03626922 | Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients | unknown | Phase 1 | 33 | NSABP Foundation IncNETWORK | 1 | Jun 10, 2022 | clinicaltrials |
| NCT05410041 | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies | unknown | Phase 1 | 15 | Beijing Boren HospitalOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT04831658 | A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Mingzhi ZhangOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04982146 | Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei | unknown | Phase 1 | 10 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05398614 | SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies | unknown | Phase 1 | 18 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05396326 | A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer | unknown | Phase 1 | 20 | Shanghai Zhongshan HospitalOTHER | 0 | May 31, 2022 | clinicaltrials |
| NCT05394415 | Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC(LATE) | unknown | Phase 1 / Phase 2 | 30 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05387226 | Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma | unknown | Phase 1 | 6 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 0 | May 24, 2022 | clinicaltrials |
| NCT03788083 | Intratumoral TriMix Injections in Early Breast Cancer Patients(TMBA) | unknown | Phase 1 | 36 | Universitair Ziekenhuis BrusselOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05379647 | Natural Killer (NK) Cell Therapy for B-Cell Malignancies | unknown | Phase 1 | 24 | Zhejiang UniversityOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT05374226 | A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 172 | Suzhou Kebo Ruijun Biotechnology Co., LtdINDUSTRY | 1 | May 16, 2022 | clinicaltrials |
| NCT04052412 | Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer | unknown | Phase 1 | 2 | University of TennesseeOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT03780075 | Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT04346914 | Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT04886206 | Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation(ILDA) | unknown | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT03913234 | Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 95 | Yonsei UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05339321 | Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC | unknown | Phase 1 | 36 | Peking Union Medical College HospitalOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05365204 | A Study for Optimization of 6% Hydroxyethyl Starch Based Indocyanine Green Near-infrared Fluorescence Navigated Sentinel Lymph Node Biopsy for Breast Cancer Patients | unknown | Phase 1 | 24 | National Taiwan University Hospital Hsin-Chu BranchOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05363722 | A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 80 | Shanghai Zhongshan HospitalOTHER | 0 | May 6, 2022 | clinicaltrials |
| NCT04460066 | A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma. | unknown | Phase 1 / Phase 2 | 70 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | May 4, 2022 | clinicaltrials |
| NCT04564313 | Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation | unknown | Phase 1 | 20 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT04709458 | Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | unknown | Phase 1 | 10 | Taiga Biotechnologies, Inc.INDUSTRY | 2 | May 3, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT05357196 | PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 68 | SciClone PharmaceuticalsINDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT04300673 | Radio Guided Lymph Node Dissection in Oligometastatic Prostate Cancer Patients(DETECT) | unknown | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05353894 | Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers | unknown | Phase 1 | 27 | Genoscience PharmaINDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05350852 | Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL | unknown | Phase 1 | 16 | Zhejiang UniversityOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05349266 | Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy | unknown | Phase 1 | 16 | Zhejiang UniversityOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT04073784 | Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma. | unknown | Phase 1 | 41 | Sun Yat-sen UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05340829 | Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia | unknown | Phase 1 | 18 | He HuangOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT05341193 | PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT04213404 | Ribociclib and Spartalizumab in R/M HNSCC(RISE-HN) | unknown | Phase 1 | 13 | National Taiwan University HospitalOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT03251313 | PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients | unknown | Phase 1 | 31 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04609215 | ImmunoBreast - A Phase Ib Study | unknown | Phase 1 / Phase 2 | 20 | Henrik DitzelOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05337657 | A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer | unknown | Phase 1 | 10 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05333705 | Donor Immune Cell Therapy for Acute Myeloid Leukemia | unknown | Phase 1 | 15 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02437279 | Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients(OpACIN) | unknown | Phase 1 | 20 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05329298 | A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 90 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT04058470 | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 140 | Huiqiang HuangOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05315830 | A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric | unknown | Phase 1 | 10 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05327582 | An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | unknown | Phase 1 / Phase 2 | 65 | Chinese PLA General HospitalOTHER | 1 | Apr 14, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jul 1, 2022source: clinicaltrials